Featured news from NHIVNA
HIV-related news from NAM
Interferon-free hepatitis treatment is highly effective for people with HIV and HCV co-infection in three studies
Liz Highleyman, 2015-07-29 17:00:00
Three different interferon-free regimens – sofosbuvir/ledipasvir, AbbVie's 3D regimen and grazoprevir/elbasvir – were well-tolerated and cured more than 90% of participants with HIV and HCV co-infection in three clinical trials, confirming that HIV-positive people can respond as well as HIV-negative people to modern hepatitis C treatment, according to a set of reports presented at the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last week in Vancouver, Canada.
It is estimated that about a third of people with HIV worldwide have hepatitis C virus (HCV) co-infection. Over years or decades, chronic hepatitis C can progress to serious liver disease including cirrhosis and liver cancer. People with HIV and HCV co-infection have faster disease progression than those with HCV alone, and liver disease is a leading cause of illness and death among people living with HIV. People with HIV do not respond as well to interferon-based hepatitis C treatment, but there is growing evidence that this is not the case for the new interferon-free direct-acting antiviral (DAA) regimens.
Source:1
